Sequentials face US and Canada market curbs over cancer risk
In Ottawa health officials press Canada to halt Mead Johnsons Oracon and its two rivals while the FDA weighs a broader pull for all three brands. Officials cite a study failing to prove that unopposed estrogen in sequentials raises uterine cancer risk, as 1 million US women use the regimens.
MENTIONED IN THIS ARTICLE
Washington
Canada
Ottawa
United States
Rockville
Mead Johnson
FDA
Oracon
Ortho Pharmaceutical
Syntex Laboratories
Norquen
Also Mentioned on This Page
Hal
U.S
The
Food and Drug Administration
PDA
Bristol- Myers International
New York
Health Protection Branch
Mead Johnson & Co
Govermment
BIC
Ueventi Laser
Supan Maar
REVCO
SU Deg Revco Discount Drug Centers
Diamond
Broadway & Wilmot
New Park Mall
Realty Buys
SALA
Arizona
Warners
Olga
Bali
Maidenform
Vassarette
White Sale
Burlington
Fieldcrest
Cannon
J.P. Stevens